QRS Width > 150 ms Response Ratio Calculator

Clinical calculation support · Verify results before clinical use

QRS Duration Assessment

Enter the patient's intrinsic QRS duration to view the corresponding MADIT-CRT subgroup evidence.

150ms threshold

Enter a QRS duration in milliseconds (40–300 ms). The subgroup threshold in the cited MADIT-CRT analysis was ≥150 ms. This tool summarizes trial-level evidence; it does not calculate an individual's probability of responding to CRT.

160QRS (ms)
MADIT-CRT subgroup evidence

QRS ≥150 ms

In MADIT-CRT, the CRT-D group had a lower hazard of the primary endpoint than the ICD-only group in this prespecified QRS-duration subgroup.

Hazard ratio
0.48
95% CI 0.37–0.64
Comparator
CRT-D vs ICD
Relative hazard for death or nonfatal HF event
Subgroup interaction
P = 0.001
Treatment interaction by QRS duration in MADIT-CRT
Clinical context: This is a subgroup hazard ratio for a trial endpoint, not a response ratio or an individualized prediction. Interpret CRT candidacy alongside QRS morphology, LVEF, symptoms, rhythm, guideline criteria, and the patient's overall clinical context.

About this assessment

The original tool assigned a response ratio of 1.64 for QRS duration greater than 150 ms. That number could not be verified as a response ratio from the cited MADIT-CRT primary publication and has therefore been replaced by the published subgroup hazard ratios.

MADIT-CRT compared cardiac resynchronization therapy with a defibrillator (CRT-D) against an implantable cardioverter-defibrillator (ICD) alone in selected patients with mild heart-failure symptoms, reduced left ventricular ejection fraction, and prolonged QRS duration.

Published subgroup results

Baseline QRS durationHR for primary endpoint95% CI
≥150 ms0.480.37–0.64
<150 ms1.060.74–1.52

The primary endpoint was death from any cause or a nonfatal heart-failure event. The subgroup estimates describe relative hazard in the trial population and should not be interpreted as absolute risk, a relative probability of response, or a guaranteed treatment effect for an individual patient.

Clinical considerations

  • Confirm QRS duration and morphology on a suitable ECG; do not interpret duration in isolation.
  • Consider guideline-based indications, particularly LVEF, symptoms despite guideline-directed medical therapy, rhythm, and LBBB versus non-LBBB morphology.
  • Use shared clinical decision-making; this calculator is an educational aid and does not replace guideline assessment.

References

Moss AJ, Hall WJ, Cannom DS, et al.; MADIT-CRT Trial Investigators. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med. 2009;361:1329–1338. doi:10.1056/NEJMoa0906431.
Primary trial record and abstract. PubMed record for MADIT-CRT, including trial endpoint and main results. PubMed PMID: 19723701.
Evidence limitation The HR values shown here are from the prespecified QRS-duration subgroup analysis in the primary MADIT-CRT report. They are not a validated individual CRT response prediction model.
Clinical disclaimer: This tool is for educational and clinical decision-support purposes only. It does not establish eligibility for CRT or predict an individual's response. Use current guidelines, the complete clinical assessment, ECG morphology, ventricular function, symptoms, comorbidities, and patient preferences when making treatment decisions.